Advertisement

MicroRNAs: miRRORS of health and disease

  • Monty Montano
    Correspondence
    Reprint requests: Monty Montano, Department of Medicine, Boston University Medical Campus, 650 Albany Street, EBRC 646, Boston MA 02118
    Affiliations
    Department of Medicine, Boston University Medical Campus, Boston, Mass
    Search for articles by this author
Published:February 11, 2011DOI:https://doi.org/10.1016/j.trsl.2011.02.001
      The review articles in this issue provide an improved appreciation for microRNA (miRNA) as an essential feature of lineage commitment and regulatory guidance during tissue development that, when absent or hampered, often lead to disease states. In the coming years, there is much to be learned about adaptive (and maladaptive) states by examining how the expression of miRNAs is influenced by the genetic architecture of miR genes, clusters, and mirtrons, as well as miRNA polymorphism and polymorphism in their mRNA targets. We are also introduced to several modes of miRNA regulation (negative feedback, positive feedback, and cross regulatory) that monitor, modulate, or resolve signaling pathways in a variety of biologic processes that include sepsis response, fibrosis, acute exercise, and steroid biology. Perhaps the homeostasis or micromanagement of these miRNA regulatory systems, when perturbed, arrive at new stable networked interactions that have an undesired effect of promoting or antagonizing disease severity and cancer progression. Clearly, a better understanding of these miRNA regulatory networks, as well as improved therapeutic tools for guiding miRNA expression and their targets toward desired outcomes, will be the subject of many advances in miRNA biology over the coming years.

      Abbreviations:

      IGF-1 (insulin growth factor-1), IRAK1 (interleukin-1 receptor associated kinase 1), LNA (locked nucleic acid), LPS (lipopolysaccharide), MKP-1 (MAP kinase phosphatase-1), miRNA (microRNA), RA (rheumatoid arthritis), RISC (RNA inducing silencing complex), SNP (single-nucleotide polymorphism), TGF-β (tumor necrosis factor β), TRAF6 (TNF receptor-associated factor 6), UTR (untranslated region)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Guay C.
        • Roggli E.
        • Nesca V.
        • Jacovetti C.
        • Regazzi R.
        Diabetes mellitus, a microRNA-related disease?.
        Trans Res. 2011; 157: 253-264
        • Kerr T.
        • Korenblat K.
        • Davidson N.
        MicroRNAs and liver disease.
        Trans Res. 2011; 157: 241-252
        • Nishikura K.
        Functions and regulation of RNA editing by ADAR deaminases.
        Annu Rev Biochem. 2010; 79: 321-349
        • Dai R.
        • Ahmed A.
        MicroRNA, a new paradigm for understanding immunoregulation, inflammation and autoimmune diseases.
        Trans Res. 2011; 157: 163-179
        • Nana-Sinkham P.
        • Croce C.
        MicroRNA as therapeutic targets in cancer.
        Trans Res. 2011; 157: 216-225
        • Bartel D.P.
        MicroRNAs: genomics, biogenesis, mechanism, and function.
        Cell. 2004; 116: 281-297
        • Liu X.
        • Sempere L.
        • Guo Y.
        • et al.
        Involvement of microRNAs in lung cancer biology and therapy.
        Trans Res. 2011; 157: 200-208
        • Dorn G.
        MicroRNAs in cardiac disease.
        Trans Res. 2011; 157: 226-235
        • Akkina S.
        • Becker B.
        MicroRNAs in kidney function and disease.
        Trans Res. 2011; 157: 236-240
        • Long K.
        • Montano M.
        RNA surveillance-an emerging role for RNA regulatory networks in aging.
        Ageing Res Rev. 2011; 10: 216-224
        • Zhou T.
        • Garcia J.
        • Zhang W.
        Integrating microRNAs into a system biology approach to acute lung injury.
        Trans Res. 2011; 157: 180-190
        • Clop A.
        • Marcq F.
        • Takeda H.
        • et al.
        A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep.
        Nat Genet. 2006; 38: 813-818
        • Bartel D.P.
        MicroRNAs: target recognition and regulatory functions.
        Cell. 2009; 136: 215-233
        • Li X.
        • Cassidy J.J.
        • Reinke C.A.
        • Fischboeck S.
        • Carthew R.W.
        A microRNA imparts robustness against environmental fluctuation during development.
        Cell. 2009; 137: 273-282
        • Pandit K.
        • Milosevic J.
        • Kaminski N.
        MicroRNAs in idiopathic pulmonary fibrosis.
        Trans Res. 2011; 157: 191-199
        • Schembri F.
        • Sridhar S.
        • Perdomo C.
        • et al.
        MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium.
        Proc Natl Acad Sci U S A. 2009; 106: 2319-2324
        • Yendamuri S.
        • Kratzke R.
        MicroRNA biomarkers in lung cancer: miRacle or quagMiRe?.
        Trans Res. 2011; 157: 209-215